Haven't had much time lately? Here's what you may have missed in the last few weeks.
Sign-up to receive the OncologyPRO alert
every 2 weeks.
Melanoma Adjuvant Setting - State of the Art , by Riccardo Marconcini
11 Dec 2018
A database review has identified a small risk of severe haematological immune-related adverse events among cancer patients using PD-1 and PD-L1...
10 Dec 2018
Phase II results show clinical benefit of the multikinase inhibitor regorafenib in the recurrent glioblastoma setting
07 Dec 2018
Thromboprophylaxis with rivaroxaban or apixaban could be an option for chemotherapy-treated cancer patients at risk of venous thromboembolism
06 Dec 2018
The BCL2 Gly101Val mutation confers resistance to venetoclax treatment in chronic lymphocytic leukaemia patients
06 Dec 2018
Reducing CHOP chemotherapy to four cycles does not reduce efficacy for younger patients with favourable-prognosis diffuse large B-cell lymphoma
Commenting on the findings from KEYNOTE-407 in metastatic squamous NSCLC and IMpower132 in metastatic non-squamous NSCLC studies presented at ESMO 2018 Congress, Dr. Silvia Novello explains that these trials show the activity of the combination therapy, chemotherapy plus immunotherapy regardless of PD-L1 status. In KEYNOTE-407, the results are positive in terms of response and overall survival, and quality of life is also improved. In IMpower132, some subgroups of patients showed a clear benefit from the combination therapy.Conclusion remarks: Dr. Novello believes that the future may be a new treatment approach not only based on chemotherapy alone or immunotherapy alone depending on PL-L1 expression, but combined chemotherapy plus immunotherapy.
13-16 Dec 2018, Geneva, Switzerland
23-25 Nov 2018, Singapore, Singapore
23-24 Nov 2018, Zurich, Switzerland
08-11 Nov 2018, Amsterdam, Netherlands
02-03 Nov 2018, Zurich, Switzerland
19-23 Oct 2018, Munich, Germany
04-05 Oct 2018, Lugano, Switzerland
28-29 Sep 2018, Valencia, Spain
28-29 Sep 2018, Athens, Greece
21-22 Sep 2018, Singapore
19-20 Sep 2018, Singapore, Singapore
14-15 Sep 2018, Paris, France
01-03 Sep 2018, Oxford, United Kingdom
20-23 Jun 2018, Barcelona, Spain
15-20 Jun 2018, Belgrade, Serbia
